Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by René Galien
Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results From Two Randomized, Controlled Phase 2b Trials
Rheumatology and Therapy
Related publications
Upadacitinib and Filgotinib: The Role of JAK1 Selective Inhibition in the Treatment of Rheumatoid Arthritis
Drugs in Context
Molecular Medicine
Pharmacology
Upadacitinib and Filgotinib: The Role of JAK1 Selective Inhibition in the Treatment of Rheumatoid Arthritis
Drugs in Context
Molecular Medicine
Pharmacology
FRI0428 the JAK1-selective Inhibitor, Filgotinib, Inhibits Inflammation Pathways Observed in an IL23-induced Psoriatic Arthritis Mouse Model
B Cells in Rheumatoid Arthritis: From Pathogenic Players to Disease Biomarkers
BioMed Research International
Immunology
Molecular Biology
Biochemistry
Microbiology
Medicine
Genetics
How Should a Clinician Interpret Results of Randomized Controlled Trials?: Interpretation of Randomized Controlled Trials
Acta medica Lituanica
Impact of Tocilizumab Monotherapy on Patient-Reported Outcomes in Patients With Rheumatoid Arthritis From Two Randomised Controlled Trials
RMD Open
Rheumatology
Allergy
Immunology
Chemerin and PEDF Are Metaflammation-Related Biomarkers of Disease Activity and Obesity in Rheumatoid Arthritis
Frontiers in Medicine
Medicine
Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-To-Target Strategy for Rheumatoid Arthritis
ClinicoEconomics and Outcomes Research
Health Policy
Economics
Econometrics
Finance
Biologic Refractory Disease in Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Annals of the Rheumatic Diseases
Immunology
Molecular Biology
Biochemistry
Rheumatology
Allergy
Genetics
